EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Unraveling the Mechanisms of Wuling Powder Against MASLD by Integrated Metabolomics–Gut Microbiota–Serum Pharmacochemistry

Huan Yang iD, Yan-Mei Tang, Shao-Cong Han, Peng-Quan Wang, Yu-Xuan Tao, Hui-Qiong Yang, Min Zhang, Min Li, Jie Yu, Xing-Xin Yang

Pharmaceuticals · 31.03.2026 · 19 (4) · 557

DOI: 10.3390/ph19040557 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 31.03.2026. Verfasst von Huan Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Science, Yunnan University of Chinese Medicine, 1076 Yuhua Road, Kunming 650500, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Yunnan Fundamental Research Projects, Yunnan Xingdian Talent Plan Innovation Team Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent chronic liver disease with no specific therapeutics. Wuling Powder (WLP) is a classic traditional Chinese medicine prescription with therapeutic potential against MASLD, yet its molecular mechanism remains unclear. This study aims to elucidate the mechanism and possible effective substances of WLP in the treatment of MASLD.

Methods

A rat MASLD model was established via high-fat diet feeding to evaluate WLP’s efficacy. Untargeted metabolomics and 16S rRNA sequencing were used to explore the effects of WLP on metabolism and gut microbiota in vivo. Serum pharmacochemistry combined with metabolomics was used to analyze the key active components and core targets of WLP against MASLD, and molecular docking and cell experiments were used to verify the relationship between them.

Results

WLP reduced hepatic lipid accumulation and pathological damage, improved lipid levels in blood liver, enhanced antioxidant capacity, and alleviated inflammation in MASLD rats. Mechanistically, WLP regulated 19 metabolic pathways. It also decreased the Firmicutes/Bacteroidota ratio and reduced the abundance of potential pathogenic bacteria (Romboutsia and Turicibacter). Thirty-one WLP-derived components were identified in serum, 13 of which were key active components for treating MASLD. These components, especially 11-deoxyalisol A and 8β-methoxyatractylenolide I, alleviated hepatic steatosis by downregulating NOS2 and PLA2G2A expression.

Conclusions

The alleviation of MASLD by WLP was mediated by the regulation of 8 metabolic pathways, alterations in the abundance of Romboutsia and Turicibacter, and the restoration of 20 metabolite levels, an effect primarily ascribed to 13 distinct pharmacodynamic components derived from WLP.

Schlagwörter

Stichwörter der Autor:innen

Wuling Powdereffective componentsgut microbiotametabolic dysfunction-associated steatotic liver diseasemetabolomics

Autor:innen und Institutionen

  • College of Pharmaceutical Science, Yunnan University of Chinese Medicine, 1076 Yuhua Road, Kunming 650500, China.
  • Yunnan Key Laboratory of Southern Medicine Utilization, 1076 Yuhua Road, Kunming 650500, China.
  • The First Clinical College, Yunnan University of Chinese Medicine, 1076 Yuhua Road, Kunming 650500, China.

ORCID-Profile: Huan Yang

Förderung

  • National Natural Science Foundation of China
  • Yunnan Fundamental Research Projects
  • Yunnan Xingdian Talent Plan Innovation Team Project

Zitieren

APA

Yang, H., Tang, Y. M., Han, S. C., Wang, P. Q., Tao, Y. X., Yang, H. Q., Zhang, M., Li, M., Yu, J., & Yang, X. X. (2026). Unraveling the Mechanisms of Wuling Powder Against MASLD by Integrated Metabolomics–Gut Microbiota–Serum Pharmacochemistry. Pharmaceuticals, 19(4), 557. https://doi.org/10.3390/ph19040557

Vancouver

Yang H, Tang YM, Han SC, Wang PQ, Tao YX, Yang HQ, et al. Unraveling the Mechanisms of Wuling Powder Against MASLD by Integrated Metabolomics–Gut Microbiota–Serum Pharmacochemistry. Pharmaceuticals. 2026;19(4):557. doi:10.3390/ph19040557

BibTeX
@article{Yang2026,
  author = {Yang, Huan and Tang, Yan-Mei and Han, Shao-Cong and Wang, Peng-Quan and Tao, Yu-Xuan and Yang, Hui-Qiong and Zhang, Min and Li, Min and Yu, Jie and Yang, Xing-Xin},
  title = {Unraveling the Mechanisms of Wuling Powder Against MASLD by Integrated Metabolomics–Gut Microbiota–Serum Pharmacochemistry},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {4},
  pages = {557},
  doi = {10.3390/ph19040557}
}
Kostenlos starten →